Cargando…
A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients
This study aims to analyze in depth the role of IFNα in the upregulation of BLyS in different leukocyte populations and the possible relationship of these molecules with IL-17 and other pathogenic cytokines in SLE. Thus, IFNAR1 and membrane BLyS (mBLyS) expression was upregulated on various blood ce...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742957/ https://www.ncbi.nlm.nih.gov/pubmed/26847824 http://dx.doi.org/10.1038/srep20651 |
_version_ | 1782414279330234368 |
---|---|
author | López, Patricia Rodríguez-Carrio, Javier Caminal-Montero, Luis Mozo, Lourdes Suárez, Ana |
author_facet | López, Patricia Rodríguez-Carrio, Javier Caminal-Montero, Luis Mozo, Lourdes Suárez, Ana |
author_sort | López, Patricia |
collection | PubMed |
description | This study aims to analyze in depth the role of IFNα in the upregulation of BLyS in different leukocyte populations and the possible relationship of these molecules with IL-17 and other pathogenic cytokines in SLE. Thus, IFNAR1 and membrane BLyS (mBLyS) expression was upregulated on various blood cell types from patients and closely correlated in all individuals. Moreover, BLyS serum levels associated positively with IFNα and IL-17A amounts, as well as with mBLyS on B cells and neutrophils. Interestingly, mBLyS on neutrophils was also correlated with IL-17A levels. Additionally, intracellular IL-17A expression was increased in both CD4(+) lymphocytes and neutrophils from patients, and IL-17(+)CD4(+) T cell frequency was associated with serum IFNα and IFNRA1 expression on B cells. Finally, in vitro assays support an IFNα role in the activation of Th17 cells in SLE. In conclusion, these data suggest that IFNα, BLyS and IL-17 could form a pathological axis in SLE, involving T and B lymphocytes, monocytes, DCs and neutrophils, which act in a vicious circle that encourage the preexisting inflammation and propagate the disease process. |
format | Online Article Text |
id | pubmed-4742957 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-47429572016-02-09 A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients López, Patricia Rodríguez-Carrio, Javier Caminal-Montero, Luis Mozo, Lourdes Suárez, Ana Sci Rep Article This study aims to analyze in depth the role of IFNα in the upregulation of BLyS in different leukocyte populations and the possible relationship of these molecules with IL-17 and other pathogenic cytokines in SLE. Thus, IFNAR1 and membrane BLyS (mBLyS) expression was upregulated on various blood cell types from patients and closely correlated in all individuals. Moreover, BLyS serum levels associated positively with IFNα and IL-17A amounts, as well as with mBLyS on B cells and neutrophils. Interestingly, mBLyS on neutrophils was also correlated with IL-17A levels. Additionally, intracellular IL-17A expression was increased in both CD4(+) lymphocytes and neutrophils from patients, and IL-17(+)CD4(+) T cell frequency was associated with serum IFNα and IFNRA1 expression on B cells. Finally, in vitro assays support an IFNα role in the activation of Th17 cells in SLE. In conclusion, these data suggest that IFNα, BLyS and IL-17 could form a pathological axis in SLE, involving T and B lymphocytes, monocytes, DCs and neutrophils, which act in a vicious circle that encourage the preexisting inflammation and propagate the disease process. Nature Publishing Group 2016-02-05 /pmc/articles/PMC4742957/ /pubmed/26847824 http://dx.doi.org/10.1038/srep20651 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article López, Patricia Rodríguez-Carrio, Javier Caminal-Montero, Luis Mozo, Lourdes Suárez, Ana A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients |
title | A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients |
title_full | A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients |
title_fullStr | A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients |
title_full_unstemmed | A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients |
title_short | A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients |
title_sort | pathogenic ifnα, blys and il-17 axis in systemic lupus erythematosus patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742957/ https://www.ncbi.nlm.nih.gov/pubmed/26847824 http://dx.doi.org/10.1038/srep20651 |
work_keys_str_mv | AT lopezpatricia apathogenicifnablysandil17axisinsystemiclupuserythematosuspatients AT rodriguezcarriojavier apathogenicifnablysandil17axisinsystemiclupuserythematosuspatients AT caminalmonteroluis apathogenicifnablysandil17axisinsystemiclupuserythematosuspatients AT mozolourdes apathogenicifnablysandil17axisinsystemiclupuserythematosuspatients AT suarezana apathogenicifnablysandil17axisinsystemiclupuserythematosuspatients AT lopezpatricia pathogenicifnablysandil17axisinsystemiclupuserythematosuspatients AT rodriguezcarriojavier pathogenicifnablysandil17axisinsystemiclupuserythematosuspatients AT caminalmonteroluis pathogenicifnablysandil17axisinsystemiclupuserythematosuspatients AT mozolourdes pathogenicifnablysandil17axisinsystemiclupuserythematosuspatients AT suarezana pathogenicifnablysandil17axisinsystemiclupuserythematosuspatients |